Back to Results

Abivax SA ADR (ABVX)

Abivax SA ADR is a depositary receipt representing ordinary shares of Abivax SA, a clinical-stage biotechnology company focused on therapies designed to modulate the body’s immune response in chronic inflammatory diseases. The company’s lead candidate, obefazimod, is being developed in Phase 3 studies for moderately to severely active ulcerative colitis and in Phase 2b trials for Crohn’s disease. Abivax was incorporated in 2013 and is headquartered in Paris, France. The ADR is listed on NASDAQ under the ticker ABVX.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-ABVX
$110.73
5.4% Upside
Fair
$165
57.1% Upside
Bargain
Weak
0.0%
18.5x
1,612.1x
9.111 B
8.639 B
0.4%
87.6%
4.7
53.7%
Valuation • Fair Value

Abivax SA ADR (NASDAQ-ABVX) Fair Value by Valuation Model

Review the available estimates for Abivax SA ADR (NASDAQ-ABVX), including DCF Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$110.73

Estimated upside of 5.4% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$158.19

Discounted cash flow valuation reference.

Comps Fair Value

$87

Comparable-company valuation reference.

Analyst Price Target

$165

Analysts imply upside of 57.1%.

How to read these valuation models

Use the 5 available valuation references for Abivax SA ADR (NASDAQ-ABVX) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for Abivax SA ADR (NASDAQ-ABVX)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

5.687 M

Current operating scale indicator.

Revenue Forecast

5.284 M

Forward revenue estimate.

EBITDA

-293.6 M

Current operating profitability reference.

EBITDA Forecast

-300.5 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review Abivax SA ADR (NASDAQ-ABVX) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Abivax SA ADR (NASDAQ-ABVX)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

4

Mid-range quality score.

Altman Z-Score

4.7

Relatively strong balance-sheet zone.

FCF / Net Income

53.7%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Abivax SA ADR (NASDAQ-ABVX). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Dividend Profile for Abivax SA ADR (NASDAQ-ABVX)

Review the dividend metrics currently supported by the latest data.

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

The latest data indicates no current dividend yield for Abivax SA ADR (NASDAQ-ABVX). No upcoming dividend amount or event date is currently available.

Stock Forecast • Technical Outlook

Abivax SA ADR (NASDAQ-ABVX) Stock Forecast & Technical Outlook

Review Abivax SA ADR (NASDAQ-ABVX) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Neutral

The 15-minute technical read for Abivax SA ADR (NASDAQ-ABVX) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Abivax SA ADR (NASDAQ-ABVX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Abivax SA ADR (NASDAQ-ABVX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Abivax SA ADR (NASDAQ-ABVX) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Buy

The monthly technical read for Abivax SA ADR (NASDAQ-ABVX) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Abivax SA ADR (NASDAQ-ABVX)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Abivax SA ADR (NASDAQ-ABVX) has a Strong Buy consensus, with 8 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 8
Hold 0
Sell 0
FAQ • Fast Investor Answers

Abivax SA ADR (NASDAQ-ABVX) Stock FAQ

Data-supported answers about Abivax SA ADR (NASDAQ-ABVX), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$110.73
Estimated upside 5.4%
Valuation Rating
Undervalued
Estimated upside of 5.4%
Analyst Target
$165
Implied upside 57.1%
Financial Health
Weak
Current financial-health read

The current fair value estimate for Abivax SA ADR (NASDAQ-ABVX) is $110.73. This implies an estimated upside of 5.4% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 5.4% versus the current market price.

The available analyst price target for Abivax SA ADR (NASDAQ-ABVX) is $165. The analyst target implies estimated upside of 57.1%.

The current financial health read for Abivax SA ADR (NASDAQ-ABVX) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The latest available data indicates no current dividend yield for Abivax SA ADR (NASDAQ-ABVX).

The current market capitalization listed for Abivax SA ADR is 9.111 B.

The current enterprise value listed for Abivax SA ADR is 8.639 B. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Abivax SA ADR is NASDAQ-ABVX, and the stock is listed on NASDAQ.

Abivax SA ADR (NASDAQ-ABVX) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Abivax SA ADR is 0.4%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Abivax SA ADR is 87.6%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 466.4 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 208.5 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 186 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 128.8 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 78.353 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 62.595 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 61.522 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 53.245 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 40.928 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 39.9 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 32.055 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 31.841 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 28.748 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.206 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.4 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 24.131 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.214 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.751 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.546 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.864 B